Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
Sight Sciences (NASDAQ:SGHT) announced that its TearCare System has been included in the prestigious TFOS DEWS III report published in the American Journal of Ophthalmology. This recognition represents significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).
The report highlights multiple clinical studies supporting TearCare's effectiveness, including the SAHARA trial, which demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, and the OLYMPIA trial, which showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.
Sight Sciences (NASDAQ:SGHT) ha comunicato che il suo TearCare System è stato incluso nel prestigioso rapporto TFOS DEWS III pubblicato sull'American Journal of Ophthalmology. Questo riconoscimento costituisce una significativa conferma dell'efficacia clinica di TearCare nel trattamento della secchezza oculare (DED) e delle disfunzioni delle ghiandole di Meibomio (MGD).
Il rapporto mette in evidenza diversi studi clinici a supporto dell'efficacia di TearCare, tra cui il trial SAHARA, che ha mostrato la superiorità clinica rispetto a Restasis nel migliorare il Tear Breakup Time e la funzionalità ghiandolare, e il trial OLYMPIA, che ha rilevato un miglioramento significativo dei sintomi della DED, in particolare nei casi gravi rispetto a LipiFlow.
Sight Sciences (NASDAQ:SGHT) anunció que su TearCare System ha sido incluido en el prestigioso informe TFOS DEWS III publicado en el American Journal of Ophthalmology. Este reconocimiento supone una importante validación de la eficacia clínica de TearCare en el tratamiento del ojo seco (DED) y de la disfunción de las glándulas de Meibomio (MGD).
El informe destaca varios estudios clínicos que respaldan la eficacia de TearCare, entre ellos el ensayo SAHARA, que demostró superioridad clínica frente a Restasis mejorando el Tear Breakup Time y la función glandular, y el ensayo OLYMPIA, que mostró una mejora significativa de los síntomas de DED, especialmente en los casos graves en comparación con LipiFlow.
Sight Sciences (NASDAQ:SGHT)는 자사의 TearCare System이 American Journal of Ophthalmology에 게재된 권위 있는 TFOS DEWS III 보고서에 포함되었다고 발표했습니다. 이 인정은 건성안(DED)과 마이봄샘 기능장애(MGD) 치료에 있어 TearCare의 임상적 유효성을 강하게 뒷받침합니다.
보고서는 TearCare의 효과를 뒷받침하는 여러 임상 연구를 강조하며, 그중 SAHARA 시험은 눈물파괴시간(Tear Breakup Time)과 샘 기능 개선에서 Restasis보다 임상적 우수성을 보였고, OLYMPIA 시험은 특히 중증 환자에서 LipiFlow와 비교해 DED 증상의 유의한 개선을 입증했다고 전합니다.
Sight Sciences (NASDAQ:SGHT) a annoncé que son TearCare System a été inclus dans le prestigieux rapport TFOS DEWS III publié dans l'American Journal of Ophthalmology. Cette reconnaissance constitue une validation importante de l'efficacité clinique de TearCare dans le traitement de la sécheresse oculaire (DED) et des dysfonctionnements des glandes de Meibomius (MGD).
Le rapport met en avant plusieurs études cliniques soutenant l'efficacité de TearCare, notamment l'essai SAHARA, qui a démontré une supériorité clinique par rapport à Restasis en améliorant le Tear Breakup Time et la fonction glandulaire, et l'essai OLYMPIA, qui a montré une amélioration significative des symptômes de DED, en particulier dans les cas sévères par rapport à LipiFlow.
Sight Sciences (NASDAQ:SGHT) gab bekannt, dass sein TearCare System im renommierten TFOS DEWS III-Bericht aufgeführt wurde, der im American Journal of Ophthalmology veröffentlicht wurde. Diese Anerkennung stellt eine wichtige Bestätigung der klinischen Wirksamkeit von TearCare bei der Behandlung des trockenen Auges (DED) und der Meibom-Drüsen-Erkrankung (MGD) dar.
Der Bericht hebt mehrere klinische Studien hervor, die die Wirksamkeit von TearCare belegen, darunter die SAHARA-Studie, die eine klinische Überlegenheit gegenüber Restasis bei der Verbesserung der Tear Breakup Time und der Drüsenfunktion zeigte, sowie die OLYMPIA-Studie, die eine deutliche Verbesserung der DED-Symptome, insbesondere bei schweren Fällen im Vergleich zu LipiFlow, nachwies.
- Recognition in TFOS DEWS III report validates TearCare's clinical efficacy
- Clinical superiority demonstrated over Restasis in SAHARA trial for multiple measures
- OLYMPIA trial showed significant effectiveness, especially in severe cases compared to LipiFlow
- Strong third-party validation positions TearCare alongside leading ocular surface disease technologies
- None.
This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data
MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that its TearCare System, has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology.
“For the first time, TearCare has been officially included in the TFOS DEWS III Management and Therapy Report, widely recognized as one of the primary standards in evidence-based dry eye disease management,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “This powerful third-party validation highlights TearCare’s clinical relevance in treating meibomian gland disease (MGD) and solidifies our position alongside the most recognized technologies in ocular surface disease.”
The DEWS III report highlights multiple published studies of Sight Sciences’ TearCare® System that demonstrate its clinical efficacy:
- The six-month SAHARA randomized controlled trial (RCT), which showed that two TearCare® system treatments were clinically superior in improving Tear Breakup Time (TBUT) and multiple measures of gland function and non-inferior in Ocular Surface Disease Index (OSDI) compared to twice-daily Restasis® for the treatment of DED.
- The OLYMPIA RCT results showed a single TearCare treatment significantly alleviated the signs and symptoms in individuals with DED.
- In an OLYMPIA sub-analysis, subjects with more severe disease showed significantly greater improvements in multiple symptoms of DED compared to LipiFlow.®
“The recognition of the TearCare System as an interventional procedure within this publication is yet another strong validation of its clinical efficacy and integral role in patient care,” said Sam Garg, MD, Professor of Ophthalmology, Director of Cornea, Cataract, and Refractive Surgery, Gavin Herbert Eye Institute, University of California, Irvine. “The report itself is highly influential for clinicians refining treatment algorithms for dry eye.”
Jones L, Craig JP, Markoulli M, Karpecki P, Akpek EK, Basu S, Bitton E, Chen W, Dhaliwal DK, Dogru M, Gomes JAP, Koehler M, Mehta JS, Perez VL, Stapleton F, Sullivan DA, Tauber J, Tong L, Travé-Huarte S, Wolffsohn JS, Alves M, Baudouin C, Downie L, Giannaccare G, Horwath-Winter J, Liu Z, Koh S, Elisabeth M, Otero E, Villani E, Watson S, Yoon KC. TFOS DEWS III Management and Therapy Report. Am J Ophthalmol. 2025 Jun 2:S0002-9394(25)00274-0. doi: 10.1016/j.ajo.2025.05.039. Epub ahead of print. PMID: 40467022.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
Restasis is a registered trademark of Allergan, an AbbVie company.
LipiFlow is a registered trademark of Johnson & Johnson.
© 2025 Sight Sciences. All rights reserved.
Media contact
pr@SightSciences.com
Investor contact
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
What is the significance of TearCare's inclusion in the TFOS DEWS III report for Sight Sciences (NASDAQ:SGHT)?
How did TearCare perform compared to Restasis in the SAHARA clinical trial?
What were the key findings of the OLYMPIA trial for Sight Sciences' TearCare System?
Where was the TFOS DEWS III report featuring TearCare published?
